Timber Hill’s Ionis Pharmaceuticals IONS Stock Holding History

Timber Hill’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,721	Closed	-$392K	–	2253
2016 Q4	$417K	Sell	8,721 -19,069	-69%	-$755K	﹤0.01%	1736
2016 Q3	$1.02M	Buy	+27,790	New	+$869K	﹤0.01%	1120
2016 Q1	–	Sell	-6,773	Closed	-$275K	–	2193
2015 Q4	$419K	Sell	6,773 -4,051	-37%	-$219K	﹤0.01%	1787
2015 Q3	$438K	Buy	+10,824	New	+$560K	﹤0.01%	1866
2014 Q3	–	Sell	-8,297	Closed	-$294K	–	2709
2014 Q2	$286K	Sell	8,297 -7,959	-49%	-$251K	﹤0.01%	2439
2014 Q1	$702K	Buy	+16,256	New	+$788K	﹤0.01%	1834
2013 Q3	–	Sell	-32,947	Closed	-$984K	–	3306
2013 Q2	$885K	Buy	+32,947	New	+$701K	﹤0.01%	2053

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Timber Hill's IONS Position: Q1 2017 in Review

Timber Hill sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 8,721 shares — an estimated $392K sold.

Timber Hill first reported a position in IONS in Q2 2013 and held it in 7 quarters. The position peaked at $1.02M in Q3 2016. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

Timber Hill reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Timber Hill sold 8,721 Ionis Pharmaceuticals shares in Q1 2017, an estimated $392K.
Timber Hill first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Timber Hill's Ionis Pharmaceuticals position peaked at $1.02M in Q3 2016.
270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Timber Hill's 13F filing for Q1 2017, filed 10 May 2017.